News

Epcoritamab should be evaluated further after positive phase 1/2 results showing the agent was safe with preliminary antitumor activity.

In an interview with Targeted Oncology™, Corey S. Cutler, MD, MPH, FRCPC, discussed the impact belumosudil has made on the chronic GVHD space.

A California-based study of devimistat plus hydroxychloroquine for soft tissue sarcoma has enrolled its first patient.

The FDA has granted orphan drug designation to LYT-200 for the treatment of patients with pancreatic cancer. The drug is currently under investigation in phase 1/2 clinical trial for the treatment of pancreatic cancer and other metastatic solid tumors.

A significant reduction in the number of patients experiencing grade 3 or 4 toxicity was observed with modified dosing as ipilimumab combine with nivolumab in patients with advanced renal cell carcinoma.

Novel immuno-oncology agent, COM701 in combination with nivolumab and BMS-986207 may be safe for the treatment of patients with advanced solid tumors.

Ropeginterferon alfa-2b-njft has been granted FDA approval for the treatment of adults patients with polycythemia vera.

The PRESERVE-001 study has shown efficacy from ONC-392, a new anti-CTLA-4 antibody, as a monotherapy in patients with non–small cell lung cancer and ovarian cancer.

Phase 2 results presented during the SITC Annual Meeting show that adding intratumoral BO-112 to pembrolizumab in patients with advanced melanoma can induce durable responses.

Ronald S. Go, MD, a hematology oncologist with the Mayo Clinic, discusses treating and diagnosing histiocytic neoplasms, a rare hematologic cancer.

The novel combination of belzutifan and lenvatinib will be tested against cabozantinib in a phase 3 clinical trial of patients with advanced renal cell carcinoma.

Jeffrey Miller, MD, discusses the background of the Tri-Specific Killer Engager TRICK platform for the activation of natural killer cells for the treatment of refractory tumors, including those that are hematology-based.

Full results from the phase 3 INVICTUS trial show stable progression-free survival advantage and improved overall survival with ripretinib in patients with an advanced gastrointestinal stromal tumor.

Yuliya Mikheeva, MD, PhD, of Saint Petersburg State University, discusses the prognosis of patients with anaplastic thyroid cancer.

Over abiraterone/prednisone alone, apalutamide plus abiraterone-prednisone proves survival benefit in patients with metastatic castration resistant prostate cancer.

The novel checkpoint inhibitor, evorpacept induced responses in patients with head and neck squamous cell carcinoma and gastric cancer when used in combination with anticancer therapy and chemotherapy in a phase 1b study.

Bemcentinib is currently being studied in combination with pembrolizumab and has demonstrated a good safety profile.

Ocular adnexal region involvement remains rare, presenting in only between 1% to 5% of mantle cell lymphoma cases.

In an interview with Targeted Oncology, Rachna Shroff, MD, discusses the impact of ivosidenib’s approval on the cholangiocarcinoma space in greater detail.

DF1001 is currently being studied as both a monotherapy and a combination in a phase 1/2 study that is now recruiting across the United States.

American Oncology Network opens its third practice in Arizona with Desert Hematology Oncology.

The combination of lenvatinib and pembrolizumab is the current standard of care for ccRCC, however, most patients still experience disease progression. The addition of a third agent may lead to improvement in outcomes.

Compared with sunitinib, second-line treatment with ripretinib did not improve progression-free survival in patients with gastrointestinal stromal tumor.

The additional of nivolumab to chemotherapy improved event-free surivial in patients with resectable non-small cell lung cancer, meeting the primary end point of the CheckMate 816 trial.

The agent, EZM0414, will be explored in DLBCL, multiple myeloma, and non-multiple myeloma after the completion of a phase 1 dose-finding study.

After showing significant improvement in survival, a breakthrough therapy designation application for leronlimab has been submitted to the FDA.

TheADAGE study has shown that in both young and older patients, chemotherapy is manageable in the adjuvant setting.

Savolitinib in combination with durvalumab has been dosed to the first patient with MET-driven advanced papillary renal cell carcinoma in a phase 3 study.

Until the CONFIRM results, no phase 3 trial had demonstrated improvement survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy.